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 Abstract 
 Background : Hyperhomocysteinemia and methylenetet-
rahydrofolate reductase  (MTHFR) gene mutation have 
been postulated as a possible cause of recurrent miscar-
riage (RM). There is a wide variation in the prevalence of 
 MTHFR polymorphisms and homocysteine (Hcy) plasma 
levels among populations around the world. The present 
study was undertaken to investigate the possible asso-
ciation between hyperhomocysteinemia and its causative 
genetic or acquired factors and RM in Catalonia, a Medi-
terranean region in Spain. 
 Methods : Sixty consecutive patients with   ≥  3 unexplained 
RM and 30 healthy control women having at least one 
child but no previous miscarriage were included. Plasma 
Hcy levels,  MTHFR gene mutation, red blood cell (RBC) 
folate and vitamin B12 serum levels were measured in all 
subjects. 
 Results : No significant differences were observed neither in 
plasma Hcy levels, RBC folate and vitamin B12 serum levels 
nor in the prevalence of homozygous and heterozygous 
 MTHFR gene mutation between the two groups studied. 
 Conclusions: In the present study RM is not associated 
with hyperhomocysteinemia, and/or the  MTHFR gene 
mutation. 
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 Introduction 
 Homocysteine (Hcy) is an intermediate product of methio-
nine metabolism, an essential amino acid provided by 
dietary proteins. Part of Hcy is combined irreversibly with 
serine generating cystathionine, an enzyme-mediated 
reaction by the cystathionine beta-synthase (CBS) and the 
cofactor vitamin B6. However, most Hcy is re-methylated 
again forming methionine in a process requiring a proper 
function of several enzymes. Methionine synthase (MS) 
adds a methyl group to Hcy in the presence of vitamin B12 
as a cofactor using the 5-methyltetrahydrofolate (5-methyl-
THF) as co-substrate. 5-methyl-THF production needs an 
adequate supply of reduced folate and an appropriate 
methylentetrahydrofolate reductase (MTHFR) function. 
Therefore, impaired enzyme function or cofactor deficien-
cies can cause elevated levels of Hcy. Hence hyperhomo-
cysteinemia can be acquired by a deficiency of folates or 
vitamin B12 and B6 supply  [1 – 4] or may be genetic due to a 
 MTHFR gene mutation  [5, 6] . 
 Several published reports regarding the prevalence 
of hyperhomocysteinemia and  MTHFR gene mutation 
in women with recurrent miscarriage (RM), have shown 
dissenting and inconclusive results as evidenced in a 
systematic review and meta-analysis of the literature  [7] . 
The most common and studied  MTHFR gene mutation is 
produced by the substitution of cytosine (C) (normal) by 
thymine (T) (mutated) at nucleotide 677 (677C > T), which 
converts an alanine residue to a valine. A homozygosity 
mutation of the gene encoding MTHFR (T/T) produces 
a thermolabile variant that results in an enzyme with 
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reduced stability and specific activity  [8] . Homozygosity 
is associated with hyperhomocysteinemia  [5, 6] , and also 
heterozygosity among patients with low folate intake  [9] . 
Furthermore, the presence of the  MTHFR gene mutation 
itself has also been related to RM  [10] . 
 Hyperhomocysteinemia promotes vascular disease by 
a variety of mechanisms  [11 – 15] . Hcy also has procoagu-
lant properties  [16 – 18] . In pregnancy, elevated maternal 
Hcy concentrations are associated with defective chori-
onic villous vascularization that interferes with embryonic 
development  [19] . Although is not clear whether hyper-
homocystenemia is a cause or only an associated risk 
factor for RM, some studies have suggested that reducing 
circulating Hcy levels in these patients by the addition of 
group B vitamin supplements may have a beneficial effect 
in the subsequent pregnancy  [20 – 22] . Remarkably, to 
add further to the above discussed controversy, different 
studies have reported a wide variation in the prevalence 
of the  MTHFR gene polymorphisms and Hcy plasma levels 
among populations around the world  [23 – 28] . 
 Therefore, this study was undertaken to investigate 
the overall factors associated with hyperhomocysteine-
mia, mainly the  MTHFR C677T mutation, red blood cell 
(RBC) folate concentrations, and serum levels of vitamin 
B12 in patients with RM, a matter which, to the best of our 
knowledge, has not been previously reported in Spain. 
 Materials and methods 
 Subjects and study design 
 We included 60 patients aged 26 – 41 years (mean, 34 years) with a 
history of   ≥  3 (mean 3.44, range 3 – 5) consecutive spontaneous mis-
carriages of unknown etiology   ≤  10 weeks’ gestation (RM group). All 
patients underwent a complete diagnostic work-up for RM including 
screening for systemic diseases, diabetes mellitus, thyroid dysfunc-
tion, polycystic ovary disease, a chromosome assessment of the 
woman and her partner, uterine abnormalities, endometrial and 
hormonal luteal phase defects, endometrial and cervical infection, 
and thrombophilia (antiphospholipid antibodies, plasma levels of 
protein S and C, antithrombin, factor V Leiden and prothrombin 
G20210A mutations, acquired protein C resistance). All were negative 
for the above reported investigations. 
 The control population consisted of 30 healthy women aged  < 41 
years and having at least one healthy child (mean 1.37, range 1 – 3) 
but no previous miscarriage (control group). They were attending 
our center for routine gynecological examination during the study 
period. 
 Informed consent was obtained from all patients to be included 
in the current study which was approved by the Ethics Committee 
of the Hospital Clinic, Barcelona. All were Caucasian and from the 
same geographical area, the Autonomous Community of Catalonia, 
a Mediterranean region in Spain. All had normal renal function and 
none taken vitamin supplementation or hormonal treatment at least 
6 months before inclusion in the study. 
 The sample size and study design (2 cases/1 control) were 
decided arbitrarily but in keeping with previous studies on the sub-
ject leading to contradictory results  [29 – 31] . 
 In all women plasma Hcy, RBC folate, vitamin B12 serum lev-
els and  MTHFR gene polymorphisms were determined. In addition, 
other factors which may aff ect Hcy levels such as age of the patient, 
body mass index (BMI), renal function  [32] , and consumption of  > 10 
cigarettes/day  [33] were also taken into account. 
 Sample and data collection 
 Laboratory determinations were performed at least 6 months aft er 
the last pregnancy. All blood samples were drawn between 08.30 
and 10.00 h aft er overnight bed rest and fasting and without smoking 
(only water was allowed). To measure Hcy, blood was obtained in an 
EDTA-K tube and plasma was separated and stored at  – 80 ° C until 
analysis. Vitamin B12 was measured in a light protected serum. RBC 
folate concentration was measured in whole blood obtained in a light 
protected EDTA-K tube that was hemolyzed in a solution of ascorbic 
acid and the intraerythrocytary content was calculated according to 
patient ’ s hematocrit values. 
 Aft er processing the samples the three parameters were mea-
sured by an automated electrochemoluminescence immunoassay 
system Advia-Centaur (Siemens, Barcelona, Spain) as previously 
reported  [34 – 36] . The intra-assay coeffi  cient variations (CV) for 
Hcy, vitamin B12 and RBC folate were  < 6.8 % ,  < 7.9 % and  < 7.3 % , 
respectively. The inter-assay CV for Hcy, vitamin B12 and RBC folate 
were  < 7 % ,  < 9.8 % and  < 10.3 % , respectively. Reference ranges in our 
laboratory are: 5 – 15  μ mol/L for homocysteine, 250 – 1050 pg/mL for 
vitamin B12 and 250 – 1050 ng/dL for RBC folate. 
 DNA extraction and genotyping 
 MTHFR polymorphisms were analyzed in DNA extracted from hep-
arinized or EDTA-K blood and measured by Real Time PCR using 
primers and probes contained in the lightMix-Kit MTHFR C677T, Cat 
No 40-0095-16 (Roche Diagnostics, Barcelona, Spain). 
 The primers used were: Pr Sense: AGG CCA GCC TCT GAC TG Pr 
Reverse: AGG ACG GTG CGG TGA GAG TG and fl uorescent probes: Flu: 
TGA CCT GAA GCA CTT GAA GGA GAA GGT GTC  – FL y LC-Red640- 
CGG GAG CCG ATT TCA TCA  – PH. Using this system the wild type 
showed a melting peak at 63 ° C and the mutant a melting peak at 
54.5 ° C. 
 Statistics 
 Data were analyzed with the SPSS statistical soft ware version 14.0. 
A comparative analysis of the data was performed, obtaining fre-
quencies and percentages for qualitative variables and median and 
standard deviation (SD) for quantitative variables. The analysis of the 
diff erences between the two groups was performed using the Mann-
Whitney test for quantitative variables and the  χ 2 -test for qualitative 
variables. Then, a multivariate analysis using the enter mode was 
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performed to corroborate results. The analysis of the diff erences 
between RM patients with low and normal RBC folate levels and the 
control group was performed with the Kruskal-Wallis test for quan-
titative variables and the  χ 2 -test for qualitative variables. Statistical 
signifi cance was defi ned as a p < 0.05. 
 Results 
 The baseline patient characteristics, including creatinine 
serum levels, were similar in the two groups studied (Table 
 1 ). However, as expected, the mean number of previous 
miscarriages and term pregnancies were significantly 
higher in RM and control groups, respectively, Hcy plasma 
levels were similar in both groups (Table  2 ). In the RM 
group only one patient (1.6 % ) had plasma Hcy values  > 15 
 μ mol/L. This patient was 33 years old, had three previ-
ous spontaneous abortions between 8 and 10 weeks’ 
gestation and was homozygous (TT) for the  MTHFR gene 
mutation with normal vitamin B12 and RBC folate levels. 
In the control group, also only one patient (3.3 % ) aged 29 
years and having two children had plasma Hcy values  > 15 
 μ mol/L. She had a homozygous (TT)  MTHFR mutation and 
normal vitamin B12 and RBC folate levels. 
 There were no significant differences in RBC folate 
levels between the two groups. Nevertheless, the number 
of patients with RBC folate levels lower than normal was 
significantly higher (p < 0.02) in RM group as compared 
with controls (Table 2). Both groups were similar with 
respect to vitamin B12 serum levels and  MTHFR gene 
polymorphisms (Table 2). Results presented in Table 
2 were corroborated in a multivariate analysis model 
(Table  3 ). 
 Table  4 summarizes RBC folate levels, plasma levels 
of Hcy, serum concentrations of vitamin B12, and  MTHFR 
gene polymorphisms in RM patients having RBC folate 
within the normal range, those RM subjects with low RBC, 
and controls. As expected, mean RBC folate levels were 
significantly lower in RM patients having low values for 
this parameter as compared with RM group with normal 
RBC folate and control women. However, Hcy plasma 
levels, vitamin B12 serum levels, and  MTHFR gene poly-
morphisms were similar in the three groups considered 
(Table 4). 
 Discussion 
 RM is frustrating for both patients and clinicians because 
a causative etiology cannot be identified in more than 
50 % of the cases  [37, 38] . At present, one of the possi-
ble causes increasingly investigated in the literature 
is thrombophilic status which may alter the placental 
circulation. 
 In normal pregnancy the plasma concentrations 
of the different proteins involved in blood coagulation 
undergo changes that result in a physiological procoagu-
lant state in order to decrease hemorrhagic risk at delivery. 
However, this may increase the development of thrombo-
embolic complications especially in cases with associated 
genetic or acquired risk factors for thrombosis  [39 – 41] . 
 Hyperhomocysteinemia and the  MTHFR gene muta-






Age, years 35 ± 4 35.8 ± 3.1 NS
Body mass index, kg/m 2 23.9 ± 3.4 24.7 ± 3.9 NS
Tobacco  > 10 cigarettes/day 8 (13.3 % ) 4 (13.3 % ) NS
Term pregnancies 0.4 ± 0.5 1.3 ± 0.6  < 0.001
Previous miscarriages 3.4 ± 0.7 0  < 0.0001
Serum creatinine, μmol/L 88.40 88.40 NS
 Table 1   Patients baseline characteristics. 
 Results are expressed as median ± SD or n ( % ). NS, not significant; 






Homocysteine,  μ mol/L 7.7 ± 2.3 8.1 ± 3.3 NS
RBC folate, ng/dL 374.6 ± 189.2 401.3 ± 135.7 NS
Patients with low RBC 
folate, n
16 (26.6 % ) 1 (3.3 % )  < 0.02
Vitamin B12, pg/mL 518.2 ± 180.7 477.3 ± 146.9 NS
MTHFR
   Homo + / + (TT) 11 (18.3 % ) 4 (13.3 % ) NS
   Homo -/- (CC) 23 (38.3 % ) 13 (43.3 % ) NS
   Hetero  + /- (CT) 26 (43.3 % ) 13 (43.3 % ) NS
 Table 2   Homocysteine, red blood cell folate, vitamin B12 and 
MTHFR polymorphisms in the two groups studied. 
 Results are expressed as median ± SD or n ( % ). MTHFR, methylene-
tetrahydrofolate reductase; NS, not significant; RBC, red blood cell; 
RM, recurrent miscarriage. 
Parameter Odds ratio 95 % CI p-Value
Homocysteine 1.061 0.981 1.141
RBC folate 1.002 0.999 1.005
Vitamin B12 0.999 0.996 1.002
 Table 3   Multivariate analysis model. 
 RBC, red blood cell. 
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of studies have investigated their potential association 
with RM  [31, 42 – 52] . 
 The frequency of the homozygous  MTHFR genotype in 
Europe varies according to the geographical area studied, 
being of 6 % – 10 % in the Nordic countries and of 13 % – 18 % 
in the Mediterranean area. The Mediterranean diet, rich 
in folates, may also influence in the genotype difference 
between the north and south of Europe  [53] . Low levels of 
vitamin B12 and/or folates in association with a homo or 
heterozygous  MTHFR gene mutation can induce hyperho-
mocysteinemia; namely, this would occur as a result of an 
interaction between a genetic defect and the nutritional 
status  [6, 11] . Given the above evidence, in the present 
study we evaluated not only plasma Hcy, but also vitamin 
B12 and folate levels and  MTHFR gene polymorphisms. 
 The mean levels of plasma Hcy in the women included 
in our study were similar to those reported in other pub-
lished series in the Spanish and French general popula-
tion  [54, 55] . In addition, the prevalence of hyperhomo-
cysteinemia detected in our study (1.6 % and 3.3 % in the 
RM and control groups, respectively) is in agreement with 
that reported by other authors (2.5 % ) in a healthy Spanish 
general population using the same reference range values 
for plasma Hcy  [54] . In both studies the cases of hyper-
homocysteinemia detected were moderate ( > 15 and  < 30 
 μ L/L). Finally, the current investigation provides further 
support to previous studies reporting a similar incidence 
of hyperhomocysteinemia in RM patients and healthy 
controls  [44, 56] . 
 It could be argued that, as previously suggested  [57, 
58] , serum measurement of bioactive vitamin B12 fraction 
holotranscobalamin (holoTC) and methylmalonic acid 
(MMA) would be better diagnostic tools defining vitamin 
B12 deficiency. While the value of these tests are acknowl-
edged mainly in the research setting, in the routine 
clinical setting definite biomarker(s) of vitamin B12 
status remain(s) to be established  [32, 59] . Thus, an expert 
opinion report indicates that, as a screening test, total 
Hcy measurements are less expensive, widely available, 
and reflect both cobalamin and folate status  [32] . Also, 
a roundtable to discuss the measurement of vitamin B12 
status biomarkers in NHANES, stressed that problems 
with sensitivity and specificity of individual biomarkers 
underscore the need for including at least one biomarker 
of circulating vitamin B12 (serum vitamin B12 or holoTC) 
and one functional biomarker (MMA or total Hcy)  [59] . In 
our study, vitamin B12 and total Hcy were used according 
to our facilities. Vitamin B6 was not measured in our study 
given that the main determinants of total Hcy are intakes 
and plasma concentrations of vitamin B12 and folate, 
whereas the results regarding vitamin B6 are inconsistent 
 [60, 61] . 
 However, while serum folate, RBC folate, and plasma 
total Hcy are the three most commonly used biochemical 
indicators to assess folate status, serum folate is indica-
tive of recent folate intake and short-term status  [62, 63] . 
RBC folate better indicates folates stores and long-term 
status  [62, 63] and was thus used in the current investi-
gation. Finally, some components of Hcy metabolism 
such as 5-methyl-tetrahydrofolate (5MTHF) and S-aden-
osylmethionine (SAM) or S-adenosylhomocysteine (SAH) 
which may be involved in the pathogenesis of microvas-
cular disease  [64] were not investigated in our patients. 
However, in humans, little is known about the relationship 
between Hcy and its metabolites and microangiopathy 
and thus, it has been stressed that estimates of regulatory 
changes based on determinations of the plasma concen-
trations of these metabolites are still of limited value and 
must be used with caution  [64, 65] . 
 The role of the 677 C → T mutation in RM is contro-
versial. We found a similar incidence of the various (CC, 
CT y TT)  MTHFR polymorphisms as well as homozygous 
Variable RM with low RBC 
folate (n = 16)
RM with normal RBC 




RBC folate, ng/dL 172.1 ± 40 451.1 ± 167.5 401.3 ± 135.7  < 0.001
Homocysteine,  μ mol/L 8.12 ± 2 7.6 ± 2.4 8.1 ± 3.3 NS
Vitamin B12, pg/mL 520.3 ± 248.9 512 ± 153.3 477.3 ± 146.9 NS
MTHFR polymorphisms NS
   Homo + / + (TT) 1 (6.2 % ) 10 (22.7 % ) 4 (13.3 % )
   Homo -/- (CC) 8 (50 % ) 15 (34 % ) 13 (43.3 % )
   Hetero  + /- (CT) 7 (43.7 % ) 19 (43.1 % ) 13 (43.3 % )
 Table 4   Red blood cell folate, homocysteine, vitamin B12 and MTHFR polymorphisms in RM patients with low and normal red blood cell 
folate plasma levels and controls. 
 Results are expressed as median ± SD or n ( % ). MTHFR, methylenetetrahydrofolate reductase; NS, not significant; RBC, red blood cell; RM, 
recurrent miscarriage. 
Brought to you by | CRAI Universitat de Barcelona
Authenticated | 161.116.100.92
Download Date | 3/5/14 9:25 AM
 Creus et al.: Homocysteine and recurrent miscarriage   697
and heterozygous mutations in the two groups studied. 
This is in keeping with findings previously reported by 
other authors  [20, 66 – 68] and suggests that the  MTHFR 
gene mutation does not represent an increased risk of RM 
in our geographical environment. Vitamin B12 does not 
seem to play a role in this sense in either the present or in 
previous studies  [69, 44] , however, there are others that do 
not confirm these results  [31, 70] . 
 It is interesting to note that even though the mean 
level of RBC folate in the study group was normal and 
similar to that found in the control group, the percent-
age of patients with RBC folate concentrations below the 
normal range was significantly higher in the RM than in 
the control group. However, no patient with low levels of 
RBC folate presented associated hyperhomocysteinemia. 
The mechanism by which folate deficiency can cause 
miscarriage is not clear but it is known that folate plays a 
critical role in DNA synthesis and the regulation of DNA, 
by providing carbon groups for synthesis of both purine 
and pyrimidine and also methyl groups required for DNA 
regulation by methylation. It has been postulated that 
the rapid cellular development of the embryo could be 
harmed by the lack of proper folate levels  [71] . 
 Some studies have reported an association between 
folate deficiency and increased risk of both spontane-
ous miscarriage  [69, 72, 73] and RM  [44] . In this respect, 
a previous study by George et al.  [74] is of note showing 
that compared with a control women group, patients 
with low folate levels were at increased risk of sponta-
neous miscarriage of fetuses with abnormal karyotype, 
whereas no significant association was observed with 
the risk of a normal fetal karyotype. These authors pro-
posed that folate deficiency can produce an alteration 
in DNA synthesis and in chromosome structure from 
cells that are in a rapid division stage. However, in other 
published series low RBC folate levels did not seem to 
be involved in an increased risk of recurrent pregnancy 
loss  [56] . Further studies are clearly needed to clarify the 
role of RBC folate as a possible independent risk factor 
in these women. 
 In summary, the present study based on our small 
series of Spanish women living in the Mediterranean 
region of Catalonia, failed to show an association between 
RM and hyperhomocysteinemia, the  MTHFR gene muta-
tion or vitamin B12 deficiency. 
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